Education
About Us
Working with TipRanks
Follow Us
Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
1513 Stock Chart & Stats
HK$30.94
-HK$0.15(-0.57%)
At close: 4:00 PM EST
HK$30.94
-HK$0.15(-0.57%)
Day’s Range― - ―
52-Week RangeHK$24.85 - HK$41.85
Previous CloseN/A
Volume226.80K
Average Volume (3M)553.85K
Market Cap
HK$31.87B
Enterprise ValueHK$25.68B
Total Cash (Recent Filing)HK$11.04B
Total Debt (Recent Filing)HK$4.66B
Price to Earnings (P/E)11.2
Beta0.70
Next Earnings
Mar 25, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend Yield4.09%
Share Statistics
EPS (TTM)0.59
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio1.73
Price to Book (P/B)1.72
Price to Sales (P/S)2.02
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.99Price Target Upside-25.69% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSustained high gross and net margins indicate strong product economics and pricing power across the portfolio. Persistently healthy margins provide a durable earnings buffer versus cost shocks, support reinvestment in R&D and distribution, and underpin consistent returns on equity.
Rebounding Revenue GrowthA sharp TTM revenue re-acceleration signals regained commercial momentum and demand for the company’s drugs. If driven by product uptake and improved distribution rather than one-offs, this trend supports scale economies, future margin stability, and a stronger baseline for multi-quarter revenue visibility.
Strong Free Cash GenerationFree cash flow roughly matching net income and robust FCF growth provide durable funding for dividends, capex, and debt reduction. Reliable cash generation strengthens financial flexibility, enabling sustained investment in R&D and manufacturing capacity without overreliance on external financing.
Bears Say
Rising LeverageAn upward drift in leverage reduces balance-sheet flexibility and increases interest-cost sensitivity over time. Higher debt levels limit the company’s ability to absorb demand shocks or fund opportunistic R&D and M&A, and raise refinancing and covenant risk if operating cash flow weakens.
Uneven Cash ConversionLow and variable operating cash conversion implies working-capital swings and inconsistent collection or inventory dynamics. Over the medium term this can constrain liquidity, make funding cyclical expenses harder, and increase reliance on short-term financing during growth or seasonal peaks.
Margin VolatilityObserved fluctuations in EBITDA and other margins suggest sensitivity to product mix, pricing, or input costs. Persistent margin volatility undermines earnings predictability, complicates long-term planning and forecasting, and may pressure returns if competitive or cost dynamics persist.
Livzon Pharmaceutical Group News
1513 FAQ
What was Livzon Pharmaceutical Group Inc Class H’s price range in the past 12 months?
Livzon Pharmaceutical Group Inc Class H lowest stock price was HK$24.85 and its highest was HK$41.85 in the past 12 months.
What is Livzon Pharmaceutical Group Inc Class H’s market cap?
Livzon Pharmaceutical Group Inc Class H’s market cap is HK$31.87B.
When is Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date?
Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date is Mar 25, 2026 which is in 30 days.
How were Livzon Pharmaceutical Group Inc Class H’s earnings last quarter?
Livzon Pharmaceutical Group Inc Class H released its earnings results on Oct 23, 2025. The company reported HK$0.588 earnings per share for the quarter, missing the consensus estimate of HK$0.679 by -HK$0.09.
Is Livzon Pharmaceutical Group Inc Class H overvalued?
According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Overvalued.
Does Livzon Pharmaceutical Group Inc Class H pay dividends?
Livzon Pharmaceutical Group Inc Class H pays a Annually dividend of HK$1.199 which represents an annual dividend yield of 4.09%. See more information on Livzon Pharmaceutical Group Inc Class H dividends here
What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?
Livzon Pharmaceutical Group Inc Class H’s EPS estimate is 0.42.
How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?
Livzon Pharmaceutical Group Inc Class H has 299,807,130 shares outstanding.
What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?
Livzon Pharmaceutical Group Inc Class H reported an EPS of HK$0.588 in its last earnings report, missing expectations of HK$0.679. Following the earnings report the stock price went down -2.271%.
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?
Currently, no hedge funds are holding shares in HK:1513
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Livzon Pharmaceutical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.61%
12-Months-Change
Fundamentals
Return on Equity
14.91%
Trailing 12-Months
Asset Growth
-2.91%
Trailing 12-Months
Company Description
Livzon Pharmaceutical Group Inc Class H
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
1513 Stock 12 Month Forecast
Average Price Target
HK$22.99
▼(-25.69% Downside)
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---